Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd is poised for significant growth, primarily driven by positive key opinion leader (KOL) insights favoring its lead product, Brukinsa, which is projected to achieve peak sales of approximately $7.1 billion due to its preference over competing BTK inhibitors for new patient starts. The company's sonrotoclax, recognized as the most advanced BCL2 inhibitor, demonstrates improved efficacy and safety profiles, with expectations of surpassing the performance of established treatments like venetoclax, potentially generating peak sales of around $3.4 billion. Furthermore, BeOne's strategic initiatives in physician outreach and competitive contracting are anticipated to bolster Brukinsa's growth trajectory, with forecasts of over 40% year-over-year revenue growth leading the company toward profitable operations and positive free cash flow by 2025.

Bears say

The financial outlook for BeOne Medicines Ltd appears negative due to several critical factors. There is a risk of slower adoption rates for its commercial products, combined with potential failures in ongoing pipeline initiatives, which could significantly impact revenue generation and fair value assessments. Furthermore, the company's substantial cash burn, heightened competition in the oncology sector, and perceived geopolitical risks exacerbate uncertainties surrounding its market potential and competitive positioning.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $380.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $380.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.